Currently, the combination of abemaciclib with ERK1/2 inhibitor and cetuximab and the combination of CDK4/6 inhibitor with checkpoint inhibitors such as anti-programmed cell death 1 (PD1) therapy is being clinically tested in patients with advanced CRC [19]. The gene discussed is PDCD1; the disease is colorectal carcinoma.